

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications
under 37 CFR 1.53(b))

Attorney Docket No. **C1037/7017HCL/MAT**

First Named Inventor or Application Identifier

BRATZLER, Robert L.

Express Mail Label No. **EL711263038US**

Date of Deposit **March 5, 2001**

OLD S.N. 666666
J00000000

10/50/00

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.
See 37 CFR 1.27.
☐ Statement filed in prior application, status still proper and desired.
3. ☒ Specification - Total pages - 73
66 - pages description
1 - pages abstract
6 - pages claims 36 - Total claims
4. ☐ Drawing(s) (35 USC 113) - Total sheets
☐ Informal ☐ Formal - Total drawings
5. ☐ Oath or Declaration - Total pages
a. ☐ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
[Note Box 6 below]
i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Incorporation by Reference
(usable if Box 5b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 18.
7. ☐ Application Data Sheet, See 37 CFR 1.76

ADDRESS TO: Box Patent Application
Commissioner for Patents
Washington, DC 20231

8. ☐ CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix)
9. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☒ Computer Readable Form (CRF)
 - b. ☐ Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ X paper (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

10. ☐ Assignment Papers/cover sheet & documents(s)
11. ☐ 37 CFR 3.73(b) Statement
(when there is an assignee)
☐ Power of Attorney
12. ☐ English Translation of Document (if applicable)
13. ☐ Information Disclosure Statement/PTO-1449
☐ Copies of IDS Citations
14. ☐ Preliminary Amendment
15. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
16. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
17. ☒ This application claims priority under Title 35 §119(e), of United States Provisional Application No. 60/187,214, filed March 3, 2000, and entitled IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT OF CANCER, the entire contents of which are incorporated herein by reference.

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____, filed on _____, entitled _____ and now _____.

Prior application information: Examiner _____ Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER



23628

PATENT TRADEMARK OFFICE

20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME

Helen C. Lockhart, Reg. No. 39248

SIGNATURE

DATE

March 5, 2001

Express Mail No: EL711263038US

Date of Deposit: March 5, 2001

Attorney Docket No: C1037/7017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BRATZLER, Robert L. et al.
Filed: Herewith
For: IMMUNOSTIMULATORY NUCLEIC ACIDS AND
CANCER MEDICAMENT COMBINATION THERAPY FOR
THE TREATMENT OF CANCER


Box: Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT PURSUANT TO 37 CFR 1.821(f)

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicant encloses herewith a copy of the Sequence Listing and a computer readable diskette. Applicant's attorney states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information.

Respectfully submitted,



Helen C. Lockhart
Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Docket No.C1037/7017
March 5, 2001
X03/03/01